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Afﬁbody molecules are a class of engineered afﬁnity proteins with proven potential for therapeutic,
diagnostic and biotechnological applications. Afﬁbody molecules are small (6.5 kDa) single domain
proteins that can be isolated for high afﬁnity and speciﬁcity to any given protein target. Fifteen years
after its discovery, the Afﬁbody technology is gaining use in many groups as a tool for creating
molecular speciﬁcity wherever a small, engineering compatible tool is warranted. Here we summa-
rize recent results using this technology, propose an Afﬁbody nomenclature and give an overview of
different HER2-speciﬁc Afﬁbodymolecules. Cumulative evidence suggests that the three helical scaf-
fold domain used as basis for these molecules is highly suited to create a molecular afﬁnity handle
for vastly different applications.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Afﬁnity proteins are invaluable tools in the development of next
generation therapeutics. Their ability to selectively and with high
afﬁnity bind a given molecular structure is an essential key feature
also for in vitro and in vivo diagnostics, for basic research and for
many biotechnological applications. High afﬁnity and binding
speciﬁcity are however not the only requirements. Depending on
the therapeutic application, a drug protein must have rapid or slow
in vivo kinetic properties. In imaging, small size is key, as well as
ability to withstand the elevated temperature and harsh chemical
conditions often involved in labeling of the targeting probe. For
in vitro diagnostic purposes, minimal background interference
and compatibility with a number of detection methods are impor-
tant. As capturing agents in afﬁnity chromatography, the mole-
cules should withstand several tough regeneration procedures. In
addition, for all applications, manufacturing cost, shelf life and
intellectual property restrictions may eventually determine the
usefulness of the afﬁnity protein.
Currently, antibodies are the most successful and widespread
afﬁnity proteins for life science applications. Key to this success
is their capability to be isolated to virtually any given target withchemical Societies. Published by Ehigh afﬁnity and speciﬁcity and that the technology is readily
available. There are however also historical reasons; until about
20 years ago, the immune system was the only source of afﬁnity
proteins from which binders to a desired target could be generated
at will. Although antibodies often demonstrate strong binding and
can be selected for high selectivity, they have some intrinsic limi-
tations related to their molecular properties. The most used anti-
body type, the IgG molecule, is a large, bivalent, multidomain
protein, dependent on disulphide bonds and with complex glyco-
sylation pattern. This leads to relatively poor heat stability and a
comparatively difﬁcult and expensive manufacturing process. In
addition, antibodies use only a minor part of the molecule for anti-
gen recognition. Large domains have structural function and there
are other deﬁned binding sites that are responsible for interaction
with complement factors and various Fc-receptors. These interac-
tions may be desired or even essential for the intended application
but adds up on the complexity when evaluating the molecules. We
have learned how to generate and handle antibodies and their
derivatives throughout the years, but substantial efforts have also
been directed at ﬁnding new alternative afﬁnity proteins with im-
proved properties. Today, a number of techniques exist for in vitro
generation of large non-antibody molecular repertoires, from
which binders with high afﬁnity and speciﬁcity can be selected.
These so called alternative scaffold proteins often combine the
favorable molecular recognition properties of antibodies withlsevier B.V. All rights reserved.
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Fig. 1. Overview of selected applications of Afﬁbody molecules. Applications are divided into three research areas: therapy, imaging and biotechnology. Please note that some
constructs may be used in several application areas (e.g. enzymatic fusions in biotechnology as well as in therapy).
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of cysteines, high yield bacterial expression and the option for
using multispeciﬁc constructs. Several of these scaffolds have
made substantial scientiﬁc progress recently [1,2], and some are al-
ready in clinical trials.
In this work we will review Afﬁbody molecules as a viable and
sometimes superior alternative to antibodies and focus on recent
results in therapeutic, in vivo imaging and biotechnological appli-
cations (Fig. 1). The amount of reports on Afﬁbody molecules have
increased dramatically over the last few years, as have the number
of research groups working with Afﬁbody molecules. Therefore, we
here propose an Afﬁbody molecule nomenclature in an attempt to
facilitate comparison of results from different research groups.2. Afﬁbody technology
Representing a new class of afﬁnity ligands, Afﬁbody molecules
were originally derived from the B-domain in the immunoglobu-
lin-binding region of staphylococcal protein A [3]. The B-domain
is a relatively short cysteine-free peptide of 58 amino acids that
is folded into a three-helical bundle structure and the kinetics of
the folding reaction is one of the fastest that has been reported
[4]. The folding properties in combination with high solubility
and a relatively high thermal stability has contributed to a high sci-
entiﬁc interest. The B-domain was early mutated at key positions
mainly for enhanced chemical stability and the resulting engi-
neered variant was denoted the Z-domain [5]. The engineered Z-
domain retained its afﬁnity for the Fc part of the antibody while
the weaker afﬁnity for the Fab region was almost completely lost.Exploiting their robust nature and capacity of speciﬁcally cap-
turing a variety of different immunoglobulin species, protein A
and derivatives of its immunoglobulin-binding domains have been
widely used in biotechnology, and their suitability in a diverse set
of applications is today well-established (discussed in more detail
under Section 6). However, it was relatively early envisioned that
the favorable properties of domain Z should be advantageous in
an even broader variety of applications, resulting in the concept
of engineering new so-called Afﬁbody molecules based on the Z-
domain scaffold with speciﬁc binding for theoretically any given
target [6]. In contrast to monoclonal antibodies that may be gener-
ated by immunization of laboratory animals combined with
hybridoma technology, isolation of new afﬁnity proteins based
on non-immunoglobulin scaffolds is performed using synthetic
combinatorial libraries and in vitro selection systems (e.g. phage
display technology). Afﬁbody molecule libraries are generally
constructed by combinatorial randomization of 13 amino acid
positions in helices one and two that comprise the original
Fc-binding surface of the Z-domain [6,7]. The libraries have typi-
cally been displayed on phages, followed by biopanning against de-
sired targets. Using this strategy, Afﬁbody molecules showing
speciﬁc binding to a variety of different proteins (e.g. insulin,
ﬁbrinogen, transferrin, tumor necrosis factor-a, IL-8, gp120,
CD28, human serum albumin, IgA, IgE, IgM, HER2 and EGFR) have
been generated, demonstrating afﬁnities (KD) in the lM to pM
range [8]. Should the afﬁnity of the primary leads not sufﬁce, afﬁn-
ity maturation generally results in improved binders and may be
achieved by either helix shufﬂing or sequence alignment combined
with directed combinatorial mutagenesis [9,10]. The newly identi-
ﬁed molecules with their altered binding surface generally keep
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unique exceptions with interesting properties have been reported
[11]. Importantly, due to their small size and rapid folding proper-
ties, Afﬁbody molecules can be produced by chemical peptide syn-
thesis [12]. This alternative to recombinant bacterial production
enables site-speciﬁc incorporation of various chemical moieties,
such as ﬂuorescent probes or chelating groups for binding radioac-
tive metal atoms in a single chemical process. Furthermore, the
small size of the scaffold provides means for modular approaches,
where different Afﬁbody molecules are combined into fusion pro-
teins with multiple properties while still retaining an overall size
much smaller compared to a full-length antibody [13].
Phage display technology has traditionally been the preferred
format for selection of new or improved Afﬁbody molecules. How-
ever, today there are several more or less established alternative
technologies available. Although these technologies are different
in many aspects, some characteristics are generally important in
order to achieve a successful outcome. Selection pressure should
be focused on correct properties (e.g. high afﬁnity for the target
molecule) avoiding substantial bias, such as from expression level
or ampliﬁcation rate. The isolated clones should be easily ampliﬁed
between rounds and identiﬁed after the selection process. Other
preferred properties are functional display of the combinatorial
protein library, evolution possibilities during selection, and means
for monitoring the process in order to facilitate optimization. One
important aspect in combinatorial protein engineering is the li-
brary complexity. A larger library results in a more complete cov-
erage of the theoretical sequence space and hence a higher
probability of containing high-afﬁnity variants. Since proteins are
difﬁcult to sequence and ampliﬁcation techniques not involving
DNA are lacking, all successful selection systems are based on a
physical coupling of phenotype to genotype. As mentioned above,
the selection system should ideally be devoid of any undesired
bias. Nevertheless, in practice all technologies suffer from some de-
gree of bias, ultimately resulting in isolation of different sets of
afﬁnity proteins with different selection systems [14]. Conse-
quently, a broad panel of available and compatible methods for
generating the afﬁnity protein of choice should be an advantage.
In addition to phage display, several alternative selection technol-
ogies have been developed and evaluated for the Afﬁbody scaffold.
Microbial display-based systems, including ﬁlamentous phage
display, rely on an initial transformation ofDNAencoding the library
members to host cells. This procedure often become a limiting step
when large and complex libraries are desired, despite that protocols
for obtaining highly transformation competent cells and efﬁcient
delivery of the DNA by electroporation are available. To circumvent
this particular restriction, cell-free methods not requiring transfor-
mation for construction of the molecular library have been investi-
gated. One such technology is the microbead display system,
which has been evaluated for selection of speciﬁc Afﬁbody mole-
cules [15]. Using spiked model libraries, Afﬁbody molecules an-
chored onto small polystyrene beads could be efﬁciently selected
using ﬂow-cytometric sorting. Correspondingly, a variant of the
more established ribosome display technology has been evaluated
for similar purposes, enabling the construction of the largest Afﬁ-
body molecule libraries to date as well as isolation of novel speciﬁc
Afﬁbodymolecules to different targets (S. Grimm, P.-Å. Nygren, per-
sonal communication). Thebypassingof the transformationstep sig-
niﬁcantly simpliﬁes the library construction, and thus allows the
construction of large libraries in parallel for investigating and opti-
mizing different library designs. Moreover, in vitro evolution may
be included in the process, by applying error-prone PCR for ampliﬁ-
cation of isolated variants after each selection cycle.
Another recent alternative for selection of afﬁnity proteins from
combinatorial libraries is the protein complementation assay
(PCA), normally employed for studying natural protein–proteininteractions. In contrast to other selection systems, the target is ex-
pressed inside each cell (also harboring the afﬁnity protein vari-
ant), thus circumventing the need for target protein production
and puriﬁcation. In addition, since PCA might be based on survival
of positive clones in selective media, isolating speciﬁc variants can
be accomplished by simple cultivation. However, although elegant
in theory, the method has proven challenging in practice and sev-
eral groups have reported problems with insufﬁcient enrichment
from scFv libraries, speculating on reasons associated with unspe-
ciﬁc binding [16,17]. As a consequence, such efforts have required
a pre-enrichment step using either phage or ribosome display (for
selection of speciﬁc DARPins) [17,18]. In contrast to problems re-
ported with scFvs, Nygren and co-workers recently demonstrated
successful generation of speciﬁc Afﬁbody molecules for human
TNFa from a naïve library using PCA [19]. The approach was simi-
lar to a reported system for scFv libraries, employing a split version
of the b-lactamase enzyme and selection using ampicillin-contain-
ing medium. Since both methods are nearly identical, the success
of the latter is likely linked to the generally higher stability and sol-
ubility of the Z scaffold compared to scFv antibody fragments. It
has also been speculated that the PCA methods are not suitable
for afﬁnity maturation because of the lack of control over the con-
centration of both afﬁnity protein and target protein inside the cell
[16]. Nevertheless, Nygren and co-workers recently reported that
the afﬁnity of TNFa speciﬁc Afﬁbody molecules could be further
improved up to 10-fold by PCA selection from an afﬁnity matura-
tion library [20].
Afﬁbody libraries have also been displayed on cells for direc-
ted evolution purposes [21]. Cell display is analogous to phage
display, but the larger size of the cell enables quantitative ﬂow
cytometry for both sorting libraries and characterizing isolated
variants after selection. Using the Gram-positive bacterium
Staphylococcus carnosus and a vector system for recombinant dis-
play of proteins on the bacterial surface, high afﬁnity Afﬁbody
molecules for TNFa could be efﬁciently isolated and later charac-
terized using FACS [21]. Not surprisingly, unique sets of Afﬁbody
molecules were obtained from the staphylococcal-displayed li-
brary, from phage display [22] and from PCA [19,20], respec-
tively, although several binders were homologous (but never
identical) even across selection platforms.3. Imaging
Imaging widens and improves diagnosis of many diseases from
bone fractures and lung TBC to blood ﬂow and cancer. In cancer
diagnosis it can provide a global view of all metastatic lesions in
the body, in contrast to biopsy, which is usually restricted to the
primary tumor and a limited number of local lesions. Furthermore,
image-guided biopsy allows obtaining tissue samples from metas-
tasis, which are otherwise not amenable for biopsy. Thus, in to-
day’s routine clinical practice, anatomical imaging such as
computed tomography (CT) or magnetic resonance imaging (MRI)
are important for diagnosis, staging, restaging and monitoring of
therapy response of most common cancers. Lesions can be further
characterized by functional or molecular imaging measuring bio-
logical processes at the molecular level using single-photon emis-
sion spectroscopy (SPECT) or positron emission tomography (PET).
The vast majority of molecular imaging investigations are per-
formed using the glucose analogue 2-[18F]ﬂuoro-2-deoxy-D-glu-
cose (18F-FDG PET), which has proven its value for detection of
metastatic and recurrent disease, as well as for detection of early
treatment response [23–25]. However, 18F-FDG PET generates a
relatively non-speciﬁc readout, showing increased glucose metab-
olism without providing information on the presence of cancer-
speciﬁc cell-surface receptors such as human epidermal growth
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receptor-targeted therapy. An ideal imaging agent should have
high speciﬁcity and afﬁnity for its target. Furthermore, rapid bio-
distribution and tissue penetration leading to high local concentra-
tions at the intended sites as well as rapid clearance of unbound
tracer will allow for high contrast tumor imaging and reduced time
between injection and examination [26]. Recent studies indicate
that Afﬁbody molecules are among the most promising tracers
for HER2-speciﬁc molecular imaging, compared to antibodies, anti-
body fragments (reviewed by Tolmachev in [27]) as well as alter-
native scaffold proteins such as DARPins [28]. Among alternative
scaffold proteins, it is also the most investigated class of binders
in terms of imaging [29]. Studies in rats and mice have conﬁrmed
the efﬁcient extravasation and rapid biodistribution expected from
their small size. Thus, Afﬁbody molecules can ﬁnd and bind to their
targets within the ﬁrst hours after administration. This together
with rapid blood clearance (ﬁrst half-life about 10–20 min in rats)
allowed imaging of tumors in mouse xenografts models as early as
30–60 min after injection. The rapid in vivo pharmacokinetics
makes Afﬁbody molecules compatible with both very short-lived
positron emitting nuclides like 18F (t1/2 110 min) or 68Ga (t1/2
68 min) or gamma emitting nuclides like 99mTc (t1/2 6 h) or 111In
(t1/2 2.8 days) with longer half-lives. This is in contrast to antibod-
ies and scFv or Fab fragments, where the size and slow biodistribu-
tion prevents the use of short-lived positron emitters, due to the
mismatch of the half-live of the tracer and the radionuclide. The
development of Afﬁbody molecules for molecular imaging applica-
tions was primarily performed with different HER2-binding Afﬁ-
body molecules. The knowledge obtained from this work was
later applied also for development of EGFR- and PDGFRb-binding
Afﬁbody molecules [30] (unpublished). Fig. 2 shows the primary
structure of the original HER2-binding Afﬁbody molecule ZHER2:4
[31], two afﬁnity matured descendants ZHER2:477 and ZHER2:342 [10],
and two molecules that were modiﬁed from ZHER2:342: ZHER2:2395
[32] and ZHER2:2891 [33]. For comparison, the Z-domain scaffold
sequence is included [5].
In the ﬁrst studies Afﬁbody molecules were radiolabeled by
non-site-speciﬁc iodination or conjugation of chelators to the
e-NH2-group of lysines using amine chemistry and the results have
been summarized in several reviews [26,27,34].
Site-speciﬁc labeling of tracers is of utmost importance to allow
the production of well deﬁned and homogenous products for clin-
ical use. Labeling was obtained either by site-speciﬁc coupling of a
chelator during peptide synthesis or by incorporation of a unique
cysteine and using thiol-directed chemistry. Appreciable effort
has been applied to develop and optimize methods for 99mTc label-
ing of Afﬁbody molecules. More than 20 different constructs
having amino acid-based chelators placed either at the N- or C-ter-
minus of ZHER2:342 have been investigated. One of the lessonsFig. 2. Primary structure of HER2-binding Afﬁbody molecules used for molecular imag
derived is shown for comparison. The 13 amino acids in the binding site of Afﬁbody molec
the differences in the binding site of HER2-binding Afﬁbody molecules. Amino acids s
ZHER2:342, also called Mut-DS is modiﬁed by: C2 = homocystein, X = a-aminoisobutyric ac
the two-helix variant of the Z-domain. The three boxes indicate the position of helix 1,learned from these studies was that increasing the hydrophilicity
of the chelator lead to a switch from predominantly hepatobiliary
excretion to renal excretion. The absence of radiotracer uptake into
the gastrointestinal tract dramatically improved image contrast
(Fig. 3). The results of these studies have been summarized in
detail in a recent review [35].
The ﬁrst site-speciﬁc radiolabeling of Afﬁbody molecules was
reported by Orlova et al. [36]. In this study the Afﬁbody molecule
ZHER2:342 was produced by peptide synthesis in a single chemical
process with DOTA coupled to the N-terminal amine in the last
synthesis step, yielding DOTA-ZHER2:342-pep2 (ABY-002). ABY-002
was efﬁciently and stably labeled with 111In within 30 min at tem-
peratures in the range of 60–90 C. Biodistribution of 111In-ABY-
002 in SKOV-3 tumor bearing mice revealed efﬁcient tumor uptake
with 23% ID/g already 1 h after injection. The tumor to blood ratio
(T/B) rose from 8 after 1 h and 12 after 4 h to over 120 after 72 h. At
all time points the tumor uptake was higher than the uptake in all
other organs, except for the kidneys. Fast reduction of blood radio-
activity and accumulation in the urine indicate rapid clearance,
predominantly by renal ﬁltration. Accumulation of radioactivity
in the kidneys was expected for a small peptide labeled with the
residualizing radiometal 111In and a molecular weight below the
exclusion limit for renal ﬁltration. The rapid pharmacokinetics of
111In-ABY-002 allowed visualization of HER2 overexpressing tu-
mors as early as 1 h after injection. The gamma camera images
showed high contrast and beside the tumor and the kidneys no
other organ was visible. ABY-002 was also efﬁciently labeled with
the positron emitter 68Ga. Biodistribution and PET imaging studies
performed in mice bearing SKOV-3 tumor xenografts showed spe-
ciﬁc tumor targeting [37]. The tumor uptake of 68Ga-ABY-002 at
4 h post-injection (p.i.) was 12.4% ID/g and the T/B 31. Uptake in
all other organs except the kidneys was low.
A dual-labeling experiment, i.e. co-injection of 68Ga- and 111In-
ABY-002 in mouse xenografts allowed site-by-site comparison of
the same Afﬁbody molecule with two different radiometals, one
gamma emitter and one positron emitter. The results revealed sim-
ilar tumor uptake for both molecules. However, 68Ga-ABY-002 had
a signiﬁcantly lower amount of radioactivity in blood, lung, spleen
and the gastrointestinal tract as compared to 111In-ABY-002, lead-
ing to higher T/B and tumor-to-organ ratios. Accordingly, the im-
age contrast was slightly better on the 68Ga-ABY-002 PET images
then the 111In-ABY-002 gamma camera images of the same mice
obtained one day later after decay of the 68Ga radioactivity.
The ﬁrst clinical investigation of 68Ga- and 111In-labeld ABY-002
in three patients with metastatic breast cancer showed that HER2-
speciﬁc Afﬁbody molecules have the potential to visualize HER2-
expressing metastatic lesions. High contrast SPECT or PET images
were obtained already 2–3 h after injection. Overexpression of
HER2 in two metastases was conﬁrmed on biopsy tissue samplesing. The sequence of the Z-domain scaffold from which all Afﬁbody molecules are
ules are marked grey for HER2-binding Afﬁbody molecules. Amino acids in red show
ubstituted in the improved scaffold are marked yellow. The two-helix variant of
id and amino acids marked black were originally selected by Braisted and Wells for
2 and 3.
Fig. 3. Comparison of gamma camera images obtained 4 h p.i. with HER2-
binding Afﬁbody molecules with different N-terminal amino acid-based 99mTc
chelators. (A) 99mTc-maGGG-ZHER2:342, mice bearing a LS174T xenografts, (B)
99mTc-maSSS-ZHER2:342, mice bearing a SKOV-3 xenograft, (C) 99mTc-maEEE-
ZHER2:342, mice bearing a SKOV-3 xenograft. ma, Mercaptoacetyl-; T, tumor; K,
kidney; A, appendice. White contours surrounding the animals are superimposed.
Note the shift from primarily hepatobiliary excretion to renal excretion with
increasing hydrophilicity of the chelator. Published with permission of Bentham
Science Publishers Ltd.
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HER2 also in humans [38]. Further clinical studies are warranted to
assess the sensitivity and speciﬁcity of radiolabeled HER2-target-
ing Afﬁbody molecules.
A two-helix variant of the Afﬁbody molecule ZHER2:342 was re-
cently produced by removal of helix 3, situated on the opposite site
of the binding site and therefore not supposed to be involved in tar-
get binding [39]. The two alpha heliceswere stabilized by a disulﬁde
bridge formed between two introduced homocysteines. However,
the binding afﬁnity of the resulting molecule ZHER2:342-MUT-DS for
HER2 was approximately 200-fold lower than the three-helical
ZHER2:342. Later, this molecule was further modiﬁed by conjugation
of DOTA to the N-terminus [40]. SKOV-3 tumor uptake of 68Ga-
DOTA-ZHER2:342-MUT-DS was 4.1% ID/g and the T/B ratio 6.9 at 2 h
p.i. Tumor uptake exceeded the uptake in all other organs and all
time points except the kidneys. However, at 2 h p.i. the two-helix
variant had a 3-fold lower tumor uptake and amore than4-fold low-
erT/B ratio compared to 68Ga-ABY-002. Thus, theoriginal three-heli-
cal Afﬁbody molecule showed an overall better performance than
the two-helix variant, indicating that helix 3 is not only important
for structural stability but also for the overall performance of Afﬁ-
body molecules in tumor targeting and imaging.
The three-helix Afﬁbody molecule ZHER2:342 was recently further
improved by substitution of 11 amino acids in the scaffold. These
substitutions resulted in higher hydrophilicity, higher thermal sta-
bility, diminished background interactions with immunoglobulins,
full production ﬂexibility as well as fully retained in vitro and
in vivo functionality [33]. The resulting novel HER2 Afﬁbody mol-
ecule was designated ZHER2:2891. Further coupling of maleimido-
DOTA to the C-terminal cysteine led to the new lead candidate
drug for molecular imaging [MMA-DOTA-Cys61]-ZHER2:2891-Cys
(ABY-025). Pre-clinical characterization of ABY-025 revealed no
toxicity in rats and cynomolgus monkeys and no induction of anti-
body formation upon repeated administration in rats [41]. Ap-
proval for clinical trials has been obtained in Germany and Sweden.
Recently, 57Co, a long-lived gamma emitting surrogate for pos-
itron emitting 55Co was used for labeling of ZHER2:2395-Cys [42] and
showed favorable targeting of LS174T and SKOV-3 xenograft tu-
mors detected using gamma camera.
18F is currently the most commonly used positron emitter for
PET studies. However, 18F-labeling of small proteins and peptideswas not very well-established. Thus, two new methods, both using
different linker molecules containing a thiol-reactive maleimide
group were developed for site-speciﬁc 18F-labeling of Afﬁbody
molecules. The ﬁrst published method used N-[2-(4-[18F]ﬂuoro-
benzamido)ethyl] maleimide (18F-FBEM) for site-speciﬁc conjuga-
tion to the C-terminal cysteine of HER2-binding Afﬁbody
molecules to yield 18F-FBEM-ZHER2:342 or 18F-FBEM-ZHER2:2395
[43,44]. The second method used a bifunctional linker having a
thiol-reactive maleimide group on one end and an aldehyde-reac-
tive aminoxy group on the other end to obtain ZHER2:477-ONH2 and
(ZHER2:477)2-ONH2 [45]. The aminoxy-functionalized Afﬁbody mol-
ecules are labeled by conjugation of 4-[18F]ﬂuorobenzaldehyde
(4-18F-FBA) via formation of a stable oxime bond to obtain N-(4-
[18F]ﬂuorobenzylidene)oxime ((18F-FBO)-ZHER2:477). Efﬁcient tumor
targeting was obtained with Afﬁbody molecules 18F-labeled by
either method with a tumor uptake of 9.7% ID/g at 1 h p.i. for
18F-FBEM-ZHER2:342 and 4.8% ID/g 1 h p.i. for 18F-FBO-ZHER2:477.
The T/B ratio was 7.5 and 3.2 for 18F-FBEM-ZHER2:342 and 18F-FBO-
ZHER2:477, respectively. The amount of radioactivity in liver and kid-
ney as well as the radioactive amount in the intestine was consid-
erable higher for 18F-FBO-labeled Afﬁbody molecules, which lead
to PET images with strong signals in the gastrointestinal tract.
Magnetic resonance imaging (MRI) is a powerful tool for in vivo
anatomical and molecular imaging. Superparamagnetic iron oxide
(SPIO) particles have been investigated as label for targeting
vehicles to increase imaging contrast. Recently, a HER2-targeting
Afﬁbody was coupled to SPIO particles and shown to target tumors.
Tumor imaging contrast was seen only in animals treated with
targeted SPIO particles, demonstrating imaging utility [46].
Taken together, Afﬁbody molecules can be labeled with a large
variety of radionuclides. Thus development of Afﬁbody based
tracers both for SPECT and PET is possible. The ﬁrst clinical use
of Afﬁbody molecules showed that high quality SPECT and PET
images could be obtained within a few hours after injection. Thus
Afﬁbody molecules are well adapted for practical clinical use,
where image acquisition on the day of administration is preferred
over the imaging modalities one or several days after administra-
tion as demonstrated for antibodies or fragments thereof.4. Optical imaging
In vivooptical imaging is rapidlybeingdeveloped intoapreferred
analysis method in many labs for studying global receptor expres-
sion in live laboratory animals. One of the reasons is that themethod
facilitates study of the same labeled probe both in vitro in micros-
copy and ﬂow cytometry, as well as in vivo, using mouse-imaging
equipment. Importantly, optical labels provide an alternative to
radioactive methods, which may be difﬁcult to work with for many
labs. Work with radioactivity for imaging need dedicated facilities,
as well as expensive equipment like micro-PET or micro-SPECT de-
vises. A disadvantage with optical imaging is that the technique is
at best semi-quantitative and that the sensitivity is lower. The lower
sensitivitymay be an explanation for a somewhat surprising ﬁnding
by Capala and co-workers [47]. They compared amonomeric HER2-
speciﬁc Afﬁbody molecule, alone or as fused to an albumin binding
domain (ABD), with the antibody trastuzumab, all labeled with
Alexa Fluor 750 (a near infrared probe). In contrast tomany imaging
studies using radionuclide-conjugated Afﬁbody molecules, the best
contrast was seen with the ABD-fused Afﬁbody molecule, not the
monomeric one. A clear signal could be detected with the mono-
meric Afﬁbody molecule at about 6–8 h after injection, but it was
washed out from the tumor relatively rapidly while the ABD-fused
construct continued to accumulate, providing a better contrast than
both the monomer and the Alexa-labeled antibody at 24 and 48 h
after injection. Presumably, a high total dose on the tumor (as is
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tant for optical imaging than for radionuclide based imaging where
high contrast is pivotal.
Recently, however, successful in vivooptical imagingwithmono-
meric NIR-labeled Afﬁbody molecules speciﬁc for EGFR have been
reported [48]. The data suggest imaging usefulness of the mono-
meric format in tumors as small as 11 mg, and with detection of
the tumor from as early as 1 h after injection up to 3 days. The Afﬁ-
body molecule was compared with the natural receptor ligand,
EGF, labeledwith the sameNIR probe. Up to 1 h, binding and uptake
of both agents increased over time. After 1 h, binding and uptake of
labeled EGF decreased, whereas the signal of the labeled Afﬁbody
molecule increased, to reach its highest level at 4–6 h. Although
the signal was higher for the natural ligand EGF, EGF also induced
receptor mediated signaling, which is an unwanted property for an
invivo imaging reagent. In contrast, at high concentrations, theEGFR
imaging Afﬁbody molecule compromised the stimulatory effect of
EGF on EGFR, thus having a weak therapeutic effect if any.
One advantage of optical imaging is the possibility to use multi-
ple colors for simultaneous differentiation of several receptors
within e.g. a tumor. This principle has been shown using an
HER2-speciﬁc and an EGFR-speciﬁc Afﬁbody labeled with two dif-
ferent ﬂuorophores, respectively [48]. In mice transplanted with
both a HER2-expressing breast cancer and an EGFR-expressing
epithelial cancer, the two Afﬁbody molecules could distinctively
discriminate between the two tumors in the same animal. NIR-la-
beled Afﬁbody molecules thus seem to have the potential to
become useful in image guided diagnosis and even surgery of
either superﬁcial tumors or ones accessible to an endoscopic
camera.5. Towards therapeutic applications
For therapeutic applications, the most advanced results are with
Afﬁbody molecules targeting a payload. This is a natural conse-
quence following the detailed characterization of the molecule as
an imaging agent. In imaging, the ‘‘payload” is already present as a
radionuclide or ﬂuorescent molecule allowing for detailed charac-
terization of the organ distribution and fate of the protein. This
knowledge is essential for therapeutic applications, as a challenge
in targeted therapy is the balance between achieving a sufﬁcient
therapeutic effect on the targetwhileminimizingundesired toxic ef-
fects innormal tissues.Witha large targetingmolecule likeaprotein,
either the payload has to be very potent, or large quantities have to
be delivered, for instance by using nanoparticles or liposomes, or
by ampliﬁcation using viral delivery. A number of strategies are
being developed using Afﬁbody molecules to achieve this goal.
5.1. Targeting payloads
An attractive and highly potent class of payloads is immunotox-
ins; hybrid proteins composed of an afﬁnity recognition moiety
(often an antibody fragment) and a toxic domain derived from
plant or bacterial toxins [49]. Pseudomonas exotoxin A is a well
characterized bacterial protein toxin with proven therapeutic efﬁ-
cacy in numerous pre-clinical models as well as in clinical trials. A
fusion construct consisting of the HER2-targeting Afﬁbody mole-
cule ZHER2:342 and a truncated version of the toxin, PE38, was pro-
duced and demonstrated to bind to HER2-expressing cancer cell
lines, but not to HER2-negative ones [50]. Furthermore, immuno-
toxin induced protein expression inhibition was analyzed in cell
lines having different levels of HER2 on the cell surface, and the
therapeutic efﬁcacy was correlated to the expression level. For cells
having high HER2 expression, even 1 pM concentration of immu-
notoxin was sufﬁcient to inhibit protein synthesis (ED50) and affectcell viability [50]. In tumor bearing mice, 250 lg/kg HER2-targeted
immunotoxin (5 lg/mouse) injected three or six times was sufﬁ-
cient to eradicate large established xenografts of breast cancer (Ja-
cek Capala, NCI/NIH; F.F., personal communication). This suggests a
therapeutic utility of the fusion protein and indicates that Afﬁbody
molecules should be useful targeting molecules also for other
immunofusion proteins.
Another highly potent class of payloads is radionuclides. Tar-
geted radionuclide therapy can in fact be a closely related exten-
sion of imaging efforts. The imaging information providing exact
distribution data of a targeting vehicle can be used to estimate
the delivered therapeutic dose to a disease target, and toxic side ef-
fects for normal organs. One example is the use of the HER2-spe-
ciﬁc Afﬁbody ZHER2:342 together with radiometals attached via a
chelate. The molecule was studied for tumor imaging using 111In
as a gamma emitting diagnostic radionuclide and found to have
excellent imaging properties [51]. In biodistribution studies it
was however clear that the calculated dose to the kidney would
be too high to allow for a therapeutic effort. Therefore, vesicular
instillation in urinary bladder cancer was suggested as a new loco-
regional therapeutic regimen. Here, the small size of the Afﬁbody
molecule is believed to be instrumental to allow penetration of
the bladder wall into the tumors. DOTA-chelated ZHER2:342 was suc-
cessfully labeled with the radionuclides 90Y or 177Lu, both used
therapeutically in the clinic, and shown to have retained tumor cell
binding speciﬁcity and a favorable biodistribution proﬁle in non
tumor bearing mice [52]. Further studies should now be under-
taken to prove the therapeutic utility in relevant animal models.
One approach for systemic therapy using Afﬁbody molecules is
based on slow internalization of Afﬁbody molecules into malignant
cells [53]. Then residualizing properties of a radionuclide are not
critical for good radioactivity retention in tumors, and non-residu-
alizing radionuclides reduce renal radioactivity retention. Selection
of an optimal radiohalogen labeling chemistry enabled the design
of an 131I-HPEM-ZHER2:342-C Afﬁbody molecule providing low up-
take in kidneys [54] and demonstrating dose to tumor 2.6-fold
higher compared to dose to kidneys. Another potential Afﬁbody
conjugate for systemic therapy is the 186Re-labeled HER2-speciﬁc
maGSG-ZHER2:342. By utilizing the ability to chemically produce
the Afﬁbody molecule by peptide synthesis, and based on previous
Technetium-studies, Orlova et al. could label the molecule with
186Re and show a favorable biodistribution proﬁle with low
kidney uptake [55]. Preliminary dosimetry estimation suggests
that 186Re-maGSG-ZHER2:342 should provide a ﬁvefold higher dose
to the tumor compared to the dose to kidneys and more than
300-fold higher compared to the dose to blood, which is very
promising for therapeutic applications.
The most advanced example of use of Afﬁbody molecules for
radioimmunotherapy to date is using the same HER2-speciﬁc Afﬁ-
body molecule as described above, but fused to a small albumin
binding domain (ABD). The resulting fusion protein associates with
the serum albumin of the host and therefore adopts a much slower
kinetic proﬁle, a dramatically decreased kidney uptake, and a ﬁve-
fold increase of the delivered dose to the tumor as compared to the
non ABD-fused Afﬁbody molecule [56]. Treatment of mice bearing
HER2-expressing SKOV-3 ovary cancer microxenografts with
177Lu-Afﬁbody-ABD fusion protein completely prevented forma-
tion of tumors, in contrast to mice treated with saline or a radiola-
beled but non-targeted mock Afﬁbody-ABD fusion protein. In an
experiment with tumors with a medium level of receptor expres-
sion, there was a lower, although signiﬁcant therapeutic effect,
stressing the fact that the payload has to be very potent when
the target is not highly overexpressed. Antibodies have been exten-
sively investigated for therapeutic targeting of radionuclides [57].
Recently, Carlsson and co-workers used the HER2-binding anti-
body pertuzumab, also labeled with 177Lu and using the same
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body-ABD fusion protein described above [58]. Very encouraging
results were obtained, but in contrast to the Afﬁbody experiment,
with no curative effect. This could be due to a too low dose in
general, but it is also known that antibodies often cause a high
radioactive dose to the bone marrow due to their long circulation
half-life, which limits the total dose that can be given. To reduce
the dose to blood, antibody fragments with shorter half-lifes have
been investigated. A therapy experiment with an yttrium-90
labeled HER2-speciﬁc antibody fragment in a 54 kDa diabody for-
mat (90Y-CHX-A00-C6.5K-A diabody), resulted in a rather modest
therapeutic beneﬁt in SKOV-3 xenografted mice, possibly due to
the radioresistant nature of this tumor model [59]. As could be
expected for a small antibody fragment, onset of kidney toxicity
was seen at long term follow up, which would make it difﬁcult
to increase the therapeutic dose of the diabody, thus limiting its
therapeutic potential. As an alternative to fragments of antibodies,
or albumin association for small biomolecules, PEG has been used
to increase the half-life of biomolecules. Zahnd et al. used PEG to
modify the kinetic properties of a high afﬁnity HER2-speciﬁc
DARPin molecule (14.5 kDa) [28]. Whereas the unmodiﬁed mole-
cule might be used as an imaging candidate, high kidney values
would prevent use for radioimmunotherapy. However, by modify-
ing the DARPin with PEG60, a distribution proﬁle was obtained
that warrants further investigation for therapy. Taken together,
radiolabeled Afﬁbody molecules are noteworthy candidates as
targeting carriers for therapeutic radionuclides.
5.2. Redirecting particles
To increase the impact of a targeted drug, one can assemble
many drug molecules to be activated per targeting event, for exam-
ple by using particles. There are different strategies to develop par-
ticles, including solid particles composed of polymers, vesicular
particles like immunoliposomes, or viral particles. Afﬁbody mole-
cules are well suited to provide small particles with afﬁnity-med-
iated recognition for cellular targets. Such recognition is believed
to constitute an important step in increasing the speciﬁcity and
delivered amount of payload to e.g. unwanted cancer cells. Alexis
et al. used commercially available HER2-speciﬁc Afﬁbody mole-
cules in conjunction with chemical co-polymers to create nanopar-
ticle bioconjugates for tumor cell targeting [60]. The investigators
found that the uptake and cell killing activity was signiﬁcantly in-
creased for the HER2-targeted particles carrying the cancer drug
paclitaxel, as compared to non-targeted ones in in vitro cell stud-
ies. In another study, Canine et al. used biopolymers to develop
nanoparticles that mimic viral vectors [61]. Here, genetic engineer-
ing techniques were used to develop highly controlled, monodis-
perse amino acid-based biomimetic vectors. The biopolymers
consisted of a DNA condensing motif, a fusogenic peptide for endo-
somal disruption, a nuclear localization signal (NLS) and a C-termi-
nal HER2 targeting Afﬁbody molecule for cell speciﬁc uptake.
HER2-targeting nanoparticles, with a diameter of 80 nm, were
made by mixing plasmid DNA encoding enhanced green ﬂuores-
cent protein (EGFP) and the biopolymer at ﬁxed ratios. The nano-
particles were stable in plasma and could selectively transfect
HER2-expressing SKOV-3 cells but not PC-3 cells with low HER2
expression, as measured in ﬂow cytometry analyzing expressed
EGFP. The Afﬁbody molecule thus mediated tumor cell speciﬁc up-
take of genes in vitro.
5.3. Liposomes
Another type of particles for delivery of payloads are liposomes;
small vesicular carrier systems into which drugs can be encapsu-
lated. Thereby the pharmacokinetics of the drug is altered and it
is protected from elimination and degradation, resulting in im-proved efﬁcacy and safety. It was recently demonstrated that
EGFR-speciﬁc Afﬁbody molecules could serve as afﬁnity determi-
nants for stabilized liposomes when conjugated to a PEG-moiety
suitable for insertion in the lipid bilayer of the liposome [62]. Com-
pared to non-targeted liposomes, targeting led to internalization in
EGFR-expressing cell lines and a selective increase in cytotoxicity
towards EGFR-expressing tumor cells when using mitoxantrone-
loaded liposomes. The increased speciﬁcity is interesting, as lipo-
somes per se are large molecules and not necessarily efﬁciently
targeted by the afﬁnity ligand only, but also subject to many other
parameters inﬂuencing targeting due to their large size. Another
group working with stabilized Afﬁbody-conjugated liposomes has
addressed the challenge of opening the liposome when at the tar-
get site as a measure to increase speciﬁcity. The authors could
show temperature-induced opening of the liposomes at 41 C,
which can be achieved in vivo using focused ultrasound. Here,
the liposomes were conjugated to a HER2-speciﬁc Afﬁbody mole-
cule that mediated binding and internalization into HER2-express-
ing cells but not HER2-negative ones [63]. The notion that further
speciﬁcity by a secondary controlled opening step may be needed
in addition to tumor cell targeting is important. In fact, for many
nanoparticle approaches, it remains to be seen if therapeutically
relevant doses can be delivered to the intended site in vivo, while
sparing normal tissue.
5.4. Viral particles
Humanadenoviruses have beenused as cancer gene therapyvec-
tors, both in clinical trials and in pre-clinical experiments. To make
them useful in a therapeutic setting, their native binding to normal
tissuesmust bemuted and new speciﬁcitymust be engineered. This
can be done by genetic fusion of a suitable ligand with viral capsid
proteins. Afﬁbody molecules have been explored as retargeting li-
gands in this setting as they, in contrast tomost antibody fragments,
conveniently fold correctly in the reducing environment of the cell
cytoplasm. There are several reports on fully functional and re-tar-
geted viruses using different Afﬁbody molecules. Recently, an ade-
novirus with dual binding speciﬁcity by tandem incorporation of
two different Afﬁbody molecules into the virus ﬁber was reported
[64]. The virus particles were demonstrated to speciﬁcally infect
two different cell lines, expressing either of the targets and could
potentially be useful for increased target speciﬁcity. Anti-virus anti-
bodies pose a signiﬁcant problem in virus therapy as they neutralize
the infectivity of the virus. Interestingly, most pre-formed antibod-
ies are directed against the knob structure and Afﬁbody reengi-
neered virus particles were reported to escape recognition of
virus-directed antibodies [65,66]. Most reports on re-targeted virus
particles using Afﬁbody molecules have used a ﬂuorescent reporter
gene as read out for successful transfection. Recently however, ther-
apeutic activitywas demonstrated in vitro by Belousova et al., using
virusparticles re-targetedbyHER2-speciﬁcAfﬁbodymolecules con-
taining a thymidine kinase gene [67]. Subsequently, ganciclovir,
which is activated by thymidine kinase, was added to the cells and
a much higher therapeutic activity was seen with cells incubated
with re-targeted virus than with particles having a wild type infec-
tion machinery. This suggests that adenoviral particles redirected
by using Afﬁbody molecules warrants further investigations to-
wards use as therapeutic molecules.
5.5. Blocking applications
One advantage with a blocking targeting agent is that the effec-
tor mechanism is mediated directly in the binding action and no
effector function needs to be engineered, which reduces the risk
of toxic side effects to normal tissues. A major part of antibodies
approved for clinical use today block protein–protein interactions.
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apy (Gemtuzumab ozogamicin, Mylotarg; Ibritumomab tiuxetan,
Zevalin; and Tositumomab-I131, Bexxar), disregarding that anti-
bodies have an intrinsic payload function in the form of Fc-medi-
ated effector mechanisms. A number of different Afﬁbody
molecules have been isolated and characterized that hold the po-
tential for blocking a therapeutically relevant protein interaction.
The costimulatory signaling interaction of CD28 and CD80 between
two cell lines was for example blocked by a CD28 speciﬁc ABD-
fused Afﬁbody molecule, showing that proteins even of this small
size (12 kDa) efﬁciently can block cell–cell interactions [68]. Other
Afﬁbody molecules that bind cell-surface receptors and compete
with the natural ligand include molecules speciﬁc for: CD25, com-
peting with IL2 [69], IGF1R, competing with IGF-1 [70], EGFR, com-
peting with EGF [71], PDGFR-b, competing with PDGF-BB
(unpublished) and HER3, competing with Heregulin (unpublished).
Afﬁbody molecules can also block soluble protein ligands as
exempliﬁed with a TNFa speciﬁc Afﬁbody molecule that could
block binding of the TNF ligand to the TNF-receptor [21,22] in
in vitro studies. An interesting case is an Afﬁbody molecule speciﬁc
for the amyloid-b (Ab) peptide involved in Alzheimer’s disease
[72]. According to the amyloid hypothesis, the pathogenesis of
Alzheimer’s disease is associated with the oligomerization and
aggregation of the Ab peptide into protein plaques. The structure
of the Afﬁbody molecule in complex with Ab was solved by NMR,
revealing that two Afﬁbody molecules dimerize upon binding the
peptide [11]. Interestingly, both Afﬁbody molecules and the Ab
peptide undergo structure reorganization when binding, resulting
in a barrel formation of the Afﬁbody molecules, which in turn
encapsulate the Ab peptide. By burying the hydrophobic parts
of the aggregation prone Ab peptide, the Afﬁbody molecule inhibits
amyloid ﬁbrillation [11]. In a recent study, the same Ab-speciﬁc
Afﬁbody molecule, expressed in the brain of a Drosophila melano-
gaster model of Alzheimer’s disease, eliminated neurotoxicity by
increasing the clearance of Ab from the brain [73].
Afﬁbody molecules can bind and retain proteins in the intracel-
lular milieu indicating a potential as a therapeutic tool for targeted
gene therapy. When expressed intracellularly, Afﬁbody molecules
speciﬁc for HER2 and EGFR have been shown to bind their respec-
tive receptors in the ER and thus prevent them from being
transported to the cell surface [74,75]. For a more general
cell-blocking tool, perhaps an Afﬁbody molecule speciﬁc for the
transcription factor c-jun could be useful [76].
In summary, Afﬁbody molecules can block a range of therapeu-
tically relevant target proteins, both targets that antibodies can
access and targets that are difﬁcult to address with antibodies such
as intracellular proteins.6. Biotechnology
Due to its natural afﬁnity for several antibody species combined
with a robust structure, staphylococcal protein A has been used
extensively for bioseparation of antibodies, e.g. in afﬁnity chroma-
tography, immunoprecipitation and other bead-based assays. In
addition to the work on natural protein A, Afﬁbody AB together
with GE Healthcare have engineered improved variants of this pro-
tein, such as an alkali stabile version (denoted MabSelect SuRe) for
increased tolerance to alkali treatment during regeneration in
afﬁnity chromatography.
Based on the same concept, Afﬁbody molecules with new spec-
iﬁcities have been evaluated as capturing agents on afﬁnity chro-
matography columns for protein puriﬁcation purposes, targeting
a variety of different proteins including apolipoprotein A-1M
[77], Taq polymerase [77], the G protein of human respiratory syn-
cytial virus [78] and recombinant human factor VIII [79]. In evenmore challenging studies, speciﬁc Afﬁbody molecules have been
successfully employed for depletion of human proteins (e.g. trans-
ferrin [80], amyloid-b peptide [72] and human IgA [81]) from com-
plex body samples, such as human serum, plasma and
cerebrospinal ﬂuid. Moreover, engineered Afﬁbody-like molecules
based on the Z-domain with introduced positive and negative net
charge, respectively, have been fused as tags to various proteins
for puriﬁcation by ion exchange chromatography [82,83].
Even thoughafﬁnitybioseparationhasbeen themost extensively
evaluatedapplication, the small size and favorablebiophysical prop-
erties of Afﬁbody molecules have also brought them into other bio-
technology areas traditionally dominated by antibodies. Various
proteins have been constructed by genetic fusions with targeting
Afﬁbody molecules to enable facile detection of targeting in assays
such asWestern blotting. Exploiting thewide array of commercially
available Fc-speciﬁc secondary detection reagents, Afﬁbody mole-
culeshavebeen fused to theFcpart fromIgG, resulting in straightfor-
ward detection of the targeted protein inWestern blot experiments
as well as improved apparent afﬁnity due to the introduced biva-
lency [84]. Similarly, functional fusions of Afﬁbodymolecules to dif-
ferent enzymes (e.g. b-galactosidase and horseradish peroxidase)
have been reported [85,86], providing colorimetric read-out using
appropriate substrates as successfully demonstrated in ELISA, dot
blot assays and immunohistochemistry. Taking the approach fur-
ther, speciﬁc Afﬁbodymolecules, targeting human IgA and IgE, have
been fused to proteins on the surface of bacteria, resulting inwhole-
cell analytical tools that could be used in for example agglutination
assays or in whole-cell immunoprecipitations [87].
Related to the ELISA setup, Afﬁbody molecules have also been
investigated as afﬁnity probes in protein micro-array formats. For
example, in one such study dimeric Afﬁbody molecules with afﬁn-
ity for IgA, IgE, IgG, TNFa, Insulin and Taq polymerase, respectively,
were immobilized on thiol dextran microarray slides followed by
incubation with ﬂuorescently labeled analyte, revealing speciﬁc
binding of respective target protein with no observable cross-reac-
tivity and a limit of detection as low as 70 fM for the best perform-
ing Afﬁbody molecule [88]. Afﬁbodymolecules were also evaluated
as capture agents in a sandwich array format with unlabeled target
protein and monoclonal antibodies for detection, demonstrating
speciﬁcity in a complex serum or plasma sample [88]. Employing
Afﬁbody molecules in such sandwich assays for analysis of human
samples might also be advantageous in a cross-reactivity perspec-
tive, since human anti animal antibodies are occasionally present
which might lead to cross-linking of capture and detection anti-
bodies, resulting in elevated background signals, hence avoided
using Afﬁbody molecules [89].
Fluorescence-based assays using Afﬁbody molecules coupled to
ﬂuorescent molecules (either chemically or by genetic fusions)
have been investigated. Gräslund and co-workers reported on spe-
ciﬁc conjugation of an Oregon Green 488 dye to a C-terminal cys-
teine of a HER2-speciﬁc Afﬁbody followed by quantitative analysis
of HER2 expression levels on cancer cell lines as well as cryosec-
tions of SKOV-3 xenograft tumors [86]. Analysis was performed
using both ﬂow cytometry (for cell lines) and immunoﬂuorescent
confocal microscopy (for both cell lines and cryosections of tu-
mors). Similarly, Capala and co-workers recently published a study
in which genetic fusions of ﬂuorescent proteins to both an HER2
and EGFR-speciﬁc Afﬁbody were used for quantitative measure-
ments of corresponding receptor levels on cell lines and in tissue
using both ﬂow cytometry and confocal imaging [90].
Many tumor cells express various levels of the EGFR- and HER2-
receptors. In an attempt to evaluate if Afﬁbody molecules can
recognize and with high speciﬁcity distinguish tumor cells with a
special composition of EGFR and HER2 expression, bispeciﬁc Afﬁ-
body molecules were produced that recognized HER2 and EGFR
[13]. Simultaneous binding to two cell lines expressing either of
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cell–cell interaction analysis. The next step will be to show binding
discrimination between cell lines having various level of receptor
co-expression.
Afﬁbody molecules have also been investigated as biosensors
in FRET-based detection of analytes in solution. In one such
study [12], two different Afﬁbody molecules with afﬁnity for hu-
man IgA and IgG, respectively, were produced by solid phase
peptide synthesis, enabling site-speciﬁc conjugation of EDANS
and NBDX ﬂuorochromes at opposite ends of the Afﬁbody mole-
cules. Adding target protein to the double-labeled Afﬁbody mol-
ecules resulted in a concentration dependent shift in
ﬂuorescence ratio, induced by binding of target protein and
reduction in FRET between the acceptor and donor ﬂuorophore.
In a similar study by the same group [91], two different anti-
idiotypic Afﬁbody pairs, consisting of an idiotypic anti-target
Afﬁbody molecule and an anti-idiotypic Afﬁbody molecule com-
peting for the same binding site as the target protein, were used
for detection of unlabeled target protein in solution. The Afﬁ-
body molecules were conjugated to a FRET donor and acceptor
dye, respectively, enabling intramolecular FRET when interacting.
Following titration of targeted protein to the solution, the anti-
idiotypic interaction between the Afﬁbody molecules was
blocked by competition, resulting in decrease in FRET signal.
Finally, demonstrating the versatility of this particular class of
molecules, Afﬁbody molecules with speciﬁc afﬁnity for various
DNA polymerases are today used in products for hot start PCR,
marketed by Finnzymes OY. At room temperature, the Afﬁbody
molecule binds the polymerase, thereby acting as a polymerase
inhibitor, ensuring reduced levels of non-speciﬁc PCR products.
At polymerization temperature, the Afﬁbody molecule is dissoci-
ated, resulting in regained activity of the polymerase and ampliﬁ-
cation of the intended DNA sequence. Here, the rapid refolding
capability of Afﬁbody molecules after heating procedures is of
importance.
7. Nomenclature
Based on a series of publications by researchers at the Royal
Institute of Technology (KTH), Uppsala University and Afﬁbody
AB, Afﬁbody molecules have become a tool used by many research
groups. The number of reports on Afﬁbody technology is increasing
rapidly, involving a large variety of similar, yet different AfﬁbodyFig. 4. History of Afﬁbody molecules. Please note that the years in the text boxes for each
data as well as for the ﬁrst in vivo targeting in mice where the years correspond to themolecules. A common nomenclature denoting these reagents is
highly warranted. Afﬁbody proteins were ﬁrst described as binding
proteins based on the Z-domain derived from domain B of protein
A. The letter Z has ever since remained a ‘‘denominator”, even
though the second generation Afﬁbody molecule scaffold of today
differ signiﬁcantly from Z [33]. We suggest keeping Z as descrip-
tion for an Afﬁbody molecule in general. Next, we propose to in-
clude the name of the target against which the Afﬁbody was
originally selected, followed by a number. In early work, the num-
ber referred to the clone plate/sequence number, e.g. ZHER2:4 indi-
cating clone 4 of a HER2-binding Afﬁbody molecule [31]. Today,
numbers refer to a serial number used at the company Afﬁbody
AB and collaborators. Here, in addition to newly selected mole-
cules, also a change in the amino acid composition within the basic
58 aa sequence will result in a new number. Published variants of
the afﬁnity matured HER2-binding Afﬁbody molecule derived from
the original clone ZHER2:4 are for example ZHER2:342, ZHER2:477,
ZHER2:2395 and ZHER2:2891 (Fig. 2).
Sometimes multimeric constructs are desired, especially Afﬁ-
body dimers. To name an oligomer, we propose that the name of
the underlying molecule is put in brackets, and a number indicat-
ing the oligomeric state is used outside of the bracket. Thus, a di-
mer of ZHER2:342 would be denoted (ZHER2:342)2.
Finally, Afﬁbody molecules are readily used as fusion partners
with other molecules, such as enzymes, Fc-portion of IgG, albu-
min binding domains, bacterial toxins among others. We propose
to simply add the name of the fusion partner N- or C-terminally
of the Afﬁbody name depending on its position in the molecule.
For example, Tolmachev et al. [56] reported on the therapeutic
application of a protein construct where an albumin binding do-
main (ABD) was fused N-terminally to a dimeric HER2-binding
Afﬁbody molecule, and thus the name would be: ABD-
(ZHER2:342)2. In a recent work, ABY027 is composed of an N-ter-
minal monomeric second generation HER2-binding molecule
fused to an afﬁnity matured ABD and with a c-terminally cys-
conjugated DOTA, hence named: ZHER2:2891-ABD035-DOTA conju-
gated from ZHER2:2891-ABD035-Cys (F.F., V.T., manuscript in
preparation).
We propose this nomenclature to be used throughout the pa-
per, especially if the study involves more than one Afﬁbody mol-
ecule, and otherwise at least in the materials and methods
section. In the materials and methods section, we propose that
also puriﬁcation tags and similar extensions are indicated,event are for simplicity reasons the years of publication, except for the ﬁrst clinical
years that the actual experiments were carried out.
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8. Conclusion and outlook
In conclusion, Afﬁbody molecules represent a class of useful
afﬁnity proteins that have been investigated for a multitude of
applications over the last 15 years, including use in therapy, in
diagnostic imaging, and in biotechnology (Fig. 4). They have been
successfully tested for targeted diagnostic utility in cancer patients
with HER2-expressing metastases, and they are used as afﬁnity li-
gand in an IgG afﬁnity puriﬁcation column with annual sales of
tens of million dollars. While many different binding members
have been explored for biotechnological use, several Afﬁbody mol-
ecules with different speciﬁcities have been used for in vivo pur-
poses. Most early work on in vivo targeting has been done with
HER2 and later EGFR-targeting Afﬁbody molecules. Interesting fea-
tures with Afﬁbody molecules are their intrinsic small size, fast
folding and simple but robust non-cysteine containing structure.
As only 13 amino acid positions differ between binding members
speciﬁc for different receptors and proteins, much of the knowl-
edge and techniques on modulation and labeling of one Afﬁbody
molecule can be applied to another. Thus, labeling and character-
ization procedures for imaging purposes can be standardized, facil-
itating the development of imaging ligands. The same holds true
for targeted therapeutic payload approaches that in addition could
take advantage of target validation and preexisting knowledge ob-
tained from molecular imaging studies.
Taken together, Afﬁbody molecules have favorable properties
for development of novel therapeutic, diagnostic imaging and bio-
technological applications.
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